Cargando…

YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay

Chronic inflammation is a key pathological process in atherosclerosis. RNA binding proteins (RBPs) have been reported to play an important role in atherosclerotic plaque formation, and they could regulate the expression of inflammatory factors by phosphorylation modification. Y-box binding protein 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yaqin, Li, Zhiwei, Yang, Hongqin, Yang, Yang, Geng, Chi, Liu, Bin, Zhang, Tiantian, Liu, Siyang, Xue, Yunfei, Zhang, Hongkai, Wang, Jing, Zhao, Hongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386362/
https://www.ncbi.nlm.nih.gov/pubmed/35990936
http://dx.doi.org/10.3389/fcvm.2022.945557
_version_ 1784769792884867072
author Tang, Yaqin
Li, Zhiwei
Yang, Hongqin
Yang, Yang
Geng, Chi
Liu, Bin
Zhang, Tiantian
Liu, Siyang
Xue, Yunfei
Zhang, Hongkai
Wang, Jing
Zhao, Hongmei
author_facet Tang, Yaqin
Li, Zhiwei
Yang, Hongqin
Yang, Yang
Geng, Chi
Liu, Bin
Zhang, Tiantian
Liu, Siyang
Xue, Yunfei
Zhang, Hongkai
Wang, Jing
Zhao, Hongmei
author_sort Tang, Yaqin
collection PubMed
description Chronic inflammation is a key pathological process in atherosclerosis. RNA binding proteins (RBPs) have been reported to play an important role in atherosclerotic plaque formation, and they could regulate the expression of inflammatory factors by phosphorylation modification. Y-box binding protein 1 (YB1) is an RBP that has participated in many inflammatory diseases. Here, we found an increased expression of phosphorylated YB1 (pYB1) in atherosclerotic plaques and demonstrated that YB1 dephosphorylation reduced lipid accumulation and lesion area in the aorta in vivo. Additionally, we found that inflammatory cytokines were downregulated in the presence of YB1 dephosphorylation, particularly CCL2, which participates in the pathogenesis of atherosclerosis. Furthermore, we demonstrated that CCL2 mRNA rapid degradation was mediated by the glucocorticoid receptor-mediated mRNA decay (GMD) process during YB1 dephosphorylation, which resulted in the downregulation of CCL2 expression. In conclusion, YB1 phosphorylation affects the development of atherosclerosis through modulating inflammation, and targeting YB1 phosphorylation could be a potential strategy for the treatment of atherosclerosis by anti-inflammation.
format Online
Article
Text
id pubmed-9386362
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93863622022-08-19 YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay Tang, Yaqin Li, Zhiwei Yang, Hongqin Yang, Yang Geng, Chi Liu, Bin Zhang, Tiantian Liu, Siyang Xue, Yunfei Zhang, Hongkai Wang, Jing Zhao, Hongmei Front Cardiovasc Med Cardiovascular Medicine Chronic inflammation is a key pathological process in atherosclerosis. RNA binding proteins (RBPs) have been reported to play an important role in atherosclerotic plaque formation, and they could regulate the expression of inflammatory factors by phosphorylation modification. Y-box binding protein 1 (YB1) is an RBP that has participated in many inflammatory diseases. Here, we found an increased expression of phosphorylated YB1 (pYB1) in atherosclerotic plaques and demonstrated that YB1 dephosphorylation reduced lipid accumulation and lesion area in the aorta in vivo. Additionally, we found that inflammatory cytokines were downregulated in the presence of YB1 dephosphorylation, particularly CCL2, which participates in the pathogenesis of atherosclerosis. Furthermore, we demonstrated that CCL2 mRNA rapid degradation was mediated by the glucocorticoid receptor-mediated mRNA decay (GMD) process during YB1 dephosphorylation, which resulted in the downregulation of CCL2 expression. In conclusion, YB1 phosphorylation affects the development of atherosclerosis through modulating inflammation, and targeting YB1 phosphorylation could be a potential strategy for the treatment of atherosclerosis by anti-inflammation. Frontiers Media S.A. 2022-08-04 /pmc/articles/PMC9386362/ /pubmed/35990936 http://dx.doi.org/10.3389/fcvm.2022.945557 Text en Copyright © 2022 Tang, Li, Yang, Yang, Geng, Liu, Zhang, Liu, Xue, Zhang, Wang and Zhao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Tang, Yaqin
Li, Zhiwei
Yang, Hongqin
Yang, Yang
Geng, Chi
Liu, Bin
Zhang, Tiantian
Liu, Siyang
Xue, Yunfei
Zhang, Hongkai
Wang, Jing
Zhao, Hongmei
YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay
title YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay
title_full YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay
title_fullStr YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay
title_full_unstemmed YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay
title_short YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay
title_sort yb1 dephosphorylation attenuates atherosclerosis by promoting ccl2 mrna decay
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386362/
https://www.ncbi.nlm.nih.gov/pubmed/35990936
http://dx.doi.org/10.3389/fcvm.2022.945557
work_keys_str_mv AT tangyaqin yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT lizhiwei yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT yanghongqin yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT yangyang yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT gengchi yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT liubin yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT zhangtiantian yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT liusiyang yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT xueyunfei yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT zhanghongkai yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT wangjing yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT zhaohongmei yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay